Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Enterprise Value (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Enterprise Value for 7 consecutive years, with -$67.1 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value rose 33.21% year-over-year to -$67.1 million; the TTM value through Mar 2026 reached -$67.1 million, up 33.21%, while the annual FY2025 figure was -$71.8 million, 36.09% up from the prior year.
  • Enterprise Value hit -$67.1 million in Q1 2026 for Barinthus Biotherapeutics, up from -$71.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $211000.0 in Q4 2023 and bottomed at -$200.2 million in Q1 2022.
  • Average Enterprise Value over 5 years is -$128.1 million, with a median of -$117.6 million recorded in 2024.
  • Year-over-year, Enterprise Value soared 100.11% in 2023 and then tumbled 53319.91% in 2024.
  • Barinthus Biotherapeutics' Enterprise Value stood at -$194.1 million in 2022, then skyrocketed by 100.11% to $211000.0 in 2023, then crashed by 53319.91% to -$112.3 million in 2024, then skyrocketed by 36.09% to -$71.8 million in 2025, then increased by 6.49% to -$67.1 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$67.1 million, -$71.8 million, and -$75.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.